Dive into the archives.
- Don’t Hold Your Breath For Generic Avonex
September 16, 2009 — 11:47am ET | By George Miller
Biogen Idec has succeeded in extending patent protection for its multiple sclerosis drug Avonex to 2026, some 13 years beyond the original patent-expiration date. The IP sleight of hand comes in the form of a newly issued method-of-use patent, which also covers Avonex treatment of multiple [...]
- Hot off the ECTRIMS Press…Fewer Injection Site Reactions with Avonex
CAMBRIDGE, MA – Sept. 11, 2009 – Data from an observational phase IV study of 499 patients entitled The Swiss MS Skin Project show that multiple sclerosis (MS) patients taking AVONEX (interferon beta-1a IM) reported significantly fewer injection site reactions (ISRs) compared to patients on Betaferon (interferon beta-1b), Copaxone (glatiramer Acetate) or Rebif (interferon beta-1a). [...]
- Avonex Pre-Filled Syringes and My Wretched Side Effects
Sometimes interferons, including AVONEX, make people feel sad. If you are taking AVONEX, and feel unusually sad, you should tell a family member or friend right away and call your healthcare provider as soon as possible.
Some people have had severe allergic reactions, a drop in their red or white blood cell levels, a drop in [...]
- NIH Deepens Investment In Avonex and Copaxone Combination Study
Article Date: 22 Jul 2009 – 4:00 PDT
The first large-scale “CombiRX” clinical trial testing the combined use of FDA-approved interferon beta-1a (Avonex®) and glatiramer acetate (Copaxone®) to treat relapsing-remitting MS has just received a $19-million renewal grant from the National Institutes of Health. This is the largest MS trial ever supported by the [...]
- Teva completes enrollment in second Phase III trial
Jun 26, 2009 (Datamonitor via COMTEX) — Teva Pharmaceutical Industries, an Israeli generic pharmaceutical company, and Active Biotech, a Swedish pharmaceutical company, have completed patient enrollment for the second pivotal Phase III clinical trial, Bravo, evaluating the novel, oral once-daily immunomodulating compound, laquinimod, for the treatment of relapsing-remitting multiple sclerosis.
// Bravo is a global clinical [...]
- Biogen enrolls patients in new MS trial
Biogen Idec has enrolled its first patient in a phase 3 trial for a potential multiple sclerosis treatment that, when compared with existing therapies, would reduce the number of injections patients must receive.
The trial, called ADVANCE, will determine the efficacy and safety of Biogen’s drug target, called PEGylated interferon beta-1a, in reducing relapse rates in [...]
- Hot off the AAN press: Adding Steroid to Interferon May Slow Disease Activity
SEATTLE, April 30 — Adding methylprednisolone (Medrol) to Interferon-beta-1a (Avonex) treatment for multiple sclerosis may reduce disease activity better than interferon alone, researchers here said.
The combination of steroid and Interferon failed to meet its primary endpoint of time-to-sustained-progression in the MECOMBIN randomized controlled trial. But a host of secondary and tertiary outcomes — including functionality [...]
